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BACKGROUND: High-sensitivity cardiac troponin assays enable myocardial infarction to be ruled out earlier, but the safety and 
efficacy of this approach is uncertain. We investigated whether an early rule-out pathway is safe and effective for patients 
with suspected acute coronary syndrome.
METHODS: We performed a stepped-wedge cluster randomized controlled trial in the emergency departments of 7 acute 
care hospitals in Scotland. Consecutive patients presenting with suspected acute coronary syndrome between December 
2014 and December 2016 were included. Sites were randomized to implement an early rule-out pathway where myocardial 
infarction was excluded if high-sensitivity cardiac troponin I concentrations were <5 ng/L at presentation. During a previous 
validation phase, myocardial infarction was ruled out when troponin concentrations were <99th percentile at 6 to 12 hours 
after symptom onset. The coprimary outcome was length of stay (efficacy) and myocardial infarction or cardiac death after 
discharge at 30 days (safety). Patients were followed for 1 year to evaluate safety and other secondary outcomes.
RESULTS: We enrolled 31 492 patients (59±17 years of age [mean±SD]; 45% women) with troponin concentrations <99th 
percentile at presentation. Length of stay was reduced from 10.1±4.1 to 6.8±3.9 hours (adjusted geometric mean ratio, 
0.78 [95% CI, 0.73–0.83]; P<0.001) after implementation and the proportion of patients discharged increased from 50% to 
71% (adjusted odds ratio, 1.59 [95% CI, 1.45–1.75]). Noninferiority was not demonstrated for the 30-day safety outcome 
(upper limit of 1-sided 95% CI for adjusted risk difference, 0.70% [noninferiority margin 0.50%]; P=0.068), but the observed 
differences favored the early rule-out pathway (0.4% [57/14 700] versus 0.3% [56/16 792]). At 1 year, the safety outcome 
occurred in 2.7% (396/14 700) and 1.8% (307/16 792) of patients before and after implementation (adjusted odds ratio, 
1.02 [95% CI, 0.74–1.40]; P=0.894), and there were no differences in hospital reattendance or all-cause mortality.
CONCLUSIONS: Implementation of an early rule-out pathway for myocardial infarction reduced length of stay and hospital 
admission. Although noninferiority for the safety outcome was not demonstrated at 30 days, there was no increase in cardiac 
events at 1 year. Adoption of this pathway would have major benefits for patients and health care providers.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03005158.
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There are >20 million presentations of suspected acute coronary syndrome (ACS) each year in the United States alone,1 accounting for up to 10% of hospital 
visits and 40% of unscheduled admissions.2 Given that most 
patients do not have myocardial infarction (MI),3 the adoption 
of effective and safe pathways to rule out MI in the emer-
gency department and avoid hospital admission would have 
a major effect on patient care and health care provision.
Cardiac troponin testing is an integral component of 
the assessment of patients with suspected ACS, with 
guidelines recommending serial testing to rule in and 
rule out MI.4 The development of high-sensitivity cardiac 
troponin assays with enhanced precision at very low con-
centrations permits quantification well below the 99th per-
centile diagnostic threshold for MI.5 This advance has led 
to innovative pathways to rule out MI more rapidly, either 
at presentation or within 3 hours, that have been incorpo-
rated into clinical practice guidelines.6–14 However, these 
studies were observational, and there are few examples 
where the pathway guided patient care.15,16 The majority 
were modest in size, or enrolled selected low-risk patients, 
and therefore the true efficacy and safety of introducing 
these pathways into clinical practice remains uncertain.
Our aim was to determine the efficacy and safety 
of implementing an accelerated pathway where high-
sensitivity cardiac troponin testing is used to rule out 
MI at presentation in consecutive patients with sus-
pected ACS.
METHODS
Trial Design and Oversight
HiSTORIC (High-Sensitivity Cardiac Troponin on Presentation 
to Rule Out Myocardial Infarction) is a stepped-wedge cluster 
randomized controlled trial enrolling consecutive patients with 
suspected ACS across 7 acute care hospitals in Scotland. In 
this trial, the hospital site was the unit of randomization and 
therefore individual patient consent was not sought. Cluster 
randomization was necessary to avoid the risk of clinical error 
attributable to simultaneous use of different diagnostic path-
ways. The trial was approved by the Scotland A Research 
Ethics Committee and the conduct of the trial was periodi-
cally reviewed by an independent trial steering committee. All 
data were collected from the patient record and national reg-
istries, deidentified, and linked in a data repository (DataLoch, 
Edinburgh, United Kingdom) within secure National Health 
Service safe havens.17
Trial Population
Sites were eligible if they had the capacity to introduce the 
early rule-out pathway and returned data to the national 
registry. All patients were identified by the attending cli-
nician using an electronic form integrated into the care 
pathway at the time troponin was requested. Patients were 
eligible for inclusion if they presented to the emergency 
department or acute medical receiving unit with suspected 
ACS and had a high-sensitivity cardiac troponin I concen-
tration within the normal reference range (less than the 
sex-specific 99th percentile upper reference limit) at pre-
sentation. Patients were excluded if they presented with an 
out-of-hospital cardiac arrest or ST-segment–elevation MI, 
had been admitted previously during the trial, or were not 
resident in Scotland.
Randomization
The trial was conducted across 3 phases (Figure 1A). During 
all phases of the trial, a high-sensitivity cardiac troponin 
Clinical Perspective
What Is New?
• Patients with suspected acute coronary syndrome 
frequently attend emergency departments, but the 
majority do not have myocardial infarction.
• Among 31 492 consecutive patients presenting 
to 7 hospitals, implementation of an early rule-out 
pathway for patients with suspected acute coro-
nary syndrome reduced length of stay by 3.3 hours 
and hospital admissions by 59%.
• Noninferiority was not demonstrated, but observed 
differences in myocardial infarction or cardiac death 
at 30 days and 1 year favored the early rule-out 
pathway over standard care.
What Are the Clinical Implications?
• Existing early rule-out pathways for myocardial 
infarction are largely based on observational stud-
ies or small trials of selected patients.
• This trial provides evidence in consecutive patients 
with suspected acute coronary syndrome that the 
use of an early rule-out pathway is both safe and 
effective.
• Adoption of an early rule-out pathway for myocar-
dial infarction would have major benefits for both 
patients and health care providers.
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
High-STEACS High-Sensitivity Troponin in  
 the Evaluation of Patients With  
 Acute Coronary Syndrome
HiSTORIC  High-Sensitivity Cardiac Troponin 
on Presentation to Rule Out Myo-
cardial Infarction
LoDED  Limit of Detection and ECG 
Discharge
MI myocardial infarction
RAPID-TnT  Rapid Assessment of Possible 
ACS in the Emergency Department 
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I assay with sex-specific 99th percentile thresholds was 
used to guide care and rule in MI according to the Universal 
Definition of Myocardial Infarction.4 During a validation phase 
of 6 to 9 months, troponin testing was performed at presenta-
tion and repeated 6 to 12 hours after the onset of symptoms 
if indicated (standard care). In accordance with guidelines 
at the time of enrollment,4,18 MI was ruled out when high-
sensitivity cardiac troponin concentrations were <99th per-
centile at presentation if symptom onset was >6 hours from 
presentation or after serial testing 6 to 12 hours from symp-
tom onset in those presenting earlier. Sites were paired on 
the basis of the expected number of patients and random-
ized to implement the early rule-out pathway (intervention) 
in 1 of 3 steps during a 6-month randomization phase. All 
sites completed an implementation phase of 6 to 9 months 
calendar-matched to the validation phase where care was 
guided by the early rule-out pathway.
Intervention
The High-STEACS (High-Sensitivity Troponin in the Evaluation of 
Patients With Suspected Acute Coronary Syndrome) early rule-out 
pathway (Figure 1B) has been described previously.19,20 MI is ruled 
out in patients with troponin concentrations <5 ng/L at presenta-
tion unless they present within 2 hours of symptom onset and test-
ing is repeated 3 hours after presentation. Patients with troponin 
concentrations ≥5 ng/L at presentation are retested 3 hours after 
presentation and MI is ruled out if concentrations are unchanged 
(Δ <3 ng/L) and remain <99th percentile. To support implemen-
tation, we provided educational material and presentations at each 
Figure 1. Schematic diagram of the HiSTORIC trial design and the early rule-out pathway.
A, A high-sensitivity cardiac troponin I assay with sex-specific 99th percentile thresholds was used to guide care and rule in myocardial infarction 
during all phases of the trial. During a validation phase of at least 6 months, cardiac troponin testing was performed at presentation and was 
repeated 6 or 12 hours after the onset of symptoms if indicated. Myocardial infarction was ruled out when high-sensitivity cardiac troponin 
concentrations were <99th percentile at presentation if symptom onset was >6 hours from presentation or after serial testing 6 to 12 hours from 
symptom onset in those presenting earlier (standard care). Sites were paired on the basis of the expected number of patients and randomized to 
implement the early rule-out pathway (intervention) in 1 of 3 steps during a 6-month randomization phase. All sites completed an implementation 
phase of at least 6 months that was calendar-matched to the validation phase where patient care was guided by the early rule-out pathway. 
B, The early rule-out pathway rules out myocardial infarction at presentation in patients with cardiac troponin concentrations below a risk 
stratification threshold of 5 ng/L, unless they presented within 2 hours of symptom onset when testing was repeated 3 hours from presentation. 
Patients with cardiac troponin concentrations ≥5 ng/L at presentation are retested in the emergency department 3 hours after presentation and 
myocardial infarction is ruled out if concentrations are unchanged (Δ <3 ng/L) and remain <99th percentile diagnostic threshold. HiSTORIC 
indicates High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction.
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site, a Web app (www.highsteacs.com), and formal training for clin-
ical staff in the emergency department (Supplemental Methods 
in the Data Supplement). Throughout the trial, all sites used the 
Abbott Architect STAT high-sensitive troponin I assay to guide 
clinical decisions. This assay has an interassay coefficient of varia-
tion of <10% at 4.7 ng/L8,21 and a 99th percentile of 16 ng/L in 
women and 34 ng/L in men.22
Trial Outcomes
We used regional and national registries to follow up the 
trial population.17,23,24 Sequential hypothesis testing evaluated 
2 coprimary outcomes in an a priori–defined hierarchical 
order: the primary efficacy outcome followed by the primary 
safety outcome. The primary efficacy outcome was length 
of stay, defined as the length of time from presentation to 
the emergency department until discharge from hospital. The 
safety outcome was MI (type 1, type 4b, or type 4c) or car-
diac death after discharge, which was evaluated at 30 days 
(primary) and 1 year (secondary) after presentation. These 
events were adjudicated by a panel blind to the study phase. 
All subsequent presentations in which any troponin concen-
tration was >99th percentile were reviewed and adjudicated 
as described previously (Expanded Methods in the Data 
Supplement).17,25,26
The secondary efficacy outcome measure was the propor-
tion of patients discharged from the emergency department. 
Other safety outcome measures included MI, cardiac death, 
cardiovascular death, all-cause death, unplanned coronary 
revascularization, and reattendances for any reason after dis-
charge at 1 year. Adherence was evaluated for 3 prespecified 
components of the early rule-out pathway (Expanded Methods 
in the Data Supplement).
Statistical Analysis
The primary efficacy outcome was analyzed using a linear 
mixed-effects regression model, adjusting for hospital site 
(random effect), season, time of presentation since the start 
of the study, and an indicator variable for whether the early 
rule-out pathway had been implemented. The primary safety 
outcome was analyzed using a logistic mixed-effects regres-
sion model adjusting for the same covariates. For the primary 
efficacy analysis, length of stay was log-transformed before 
analysis and results expressed as a geometric mean ratio. If 
the analysis of the primary efficacy outcome was significant at 
the 5% level, then we planned to perform a noninferiority anal-
ysis of the primary safety outcome reporting a risk difference 
(intervention – standard care) and a 1-sided 95% CI. If the 
upper limit of the 1-sided 95% CI was below a 0.5% noninferi-
ority margin, noninferiority was established; if it was below 0%, 
superiority was established. A sensitivity analysis compared 
outcomes during the calendar-matched period in the validation 
and implementation phases using the same regression model 
as for the primary analysis but without adjustment for time or 
season. A number of other sensitivity analyses were performed 
(Expanded Methods in the Data Supplement).
Patient and Public Involvement
A patient review panel was consulted throughout the trial 
program and provided input on the educational advice 
provided to clinicians after introduction of the new pathway. 
Qualitative research capturing the views and experiences of 
patients treated within these pathways will follow in a sepa-
rate publication. Patients were not involved in the conception 
or design of the trial.
Data Sharing
The HiSTORIC trial makes use of multiple routine electronic 
health care data sources that are linked, deidentified, and held 
in the National Health Service national safe haven, which is 
accessible by approved individuals who have undertaken the 
necessary governance training. Summary data can be made 
available on request to the corresponding author.
RESULTS
Trial Sites and Population
Seven acute care hospitals were eligible, and all partici-
pated (Table I in the Data Supplement). Between De-
cember 2014 and December 2016, a total of 31 492 
consecutive patients with suspected ACS (59±17 years 
[mean±SD]; 45% women) met the inclusion criteria 
(Figure 2). There were 14 700 (47%) and 16 792 (53%) 
patients assessed before and after implementation of 
the early rule-out pathway, respectively. Clinical charac-
teristics were similar before and after implementation 
(Table 1) and across all 3 phases of the trial (Table II 
in the Data Supplement). The trial concluded in Decem-
ber 2017 with 1 year of follow-up available in 31 428 
(99.8%) patients.
Primary and Secondary Efficacy Outcomes
Length of stay was reduced from 10.1±4.1 to 6.8±3.9 
hours (adjusted geometric mean ratio, 0.78 [95% CI, 
0.73–0.83]; P<0.001) after implementation of the 
early rule-out pathway (Table 2 and Figure 3). The 
proportion of patients discharged from the emergen-
cy department without hospital admission increased 
from 50% to 71% (adjusted odds ratio, 1.59 [95% CI, 
1.45–1.75]). Adherence to all 3 prespecified compo-
nents of the early rule-out pathway was observed in 
11 600/16 792 (69%) patients.
Primary and Secondary Safety Outcomes
Before and after implementation of the early rule-out 
pathway, the primary safety outcome of MI or cardiac 
death after discharge at 30 days occurred in 57/14 700 
(0.4%) and 56/16 792 (0.3%) patients, respectively 
(Table 2), with an adjusted odds ratio of 1.97 (95% CI, 
0.95–4.08; P=0.068). Comparing the rate of the primary 
safety outcome after implementation with the rate be-
fore implementation, the upper limit of our 1-sided 95% 
CI for the adjusted risk difference was 0.70%, exceed-
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event rate at 30 days was lower than anticipated and 
our regression model and prespecified sensitivity analy-
ses gave divergent results (Table III in the Data Supple-
ment). However, there were 703 (2.2%) patients with 
MI or cardiac death after discharge at 1 year (Figure 4). 
Before and after implementation, the secondary safety 
outcome measure occurred in 396/14 700 (2.7%) and 
307/16 792 (1.8%) patients, respectively (adjusted 
odds ratio, 1.02 [95% CI, 0.74–1.40]; P=0.894). This 
comprised 238 (1.6%) patients with MI and 176 cardiac 
deaths (1.2%) during standard care, versus 184 (1.1%) 
patients with MI and 143 (0.9%) cardiac deaths after 
implementation of the early rule-out pathway. The rate of 
all other safety outcome measures at 1 year did not differ 
before and after implementation (Table 2). The findings 
were consistent in a post hoc analysis of the safety out-
come that included type 2 MI events (Table IV and Figure 
I in the Data Supplement).
Sensitivity Analysis in Calendar-Matched 
Validation and Implementation Phases
In total, 18 241 (58%) patients attended the calendar-
matched phases, with 8673 (48%) and 9568 (52%) 
evaluated during the validation and implementation 
phase, respectively (Table III in the Data Supplement). 
Length of stay was reduced from 10.6±4.1 to 6.8±4.0 
hours (adjusted geometric mean ratio, 0.65 [95% CI, 
0.62–0.68]) before and after implementation of the early 
rule-out pathway. The primary safety outcome occurred 
in 43/8673 (0.5%) and 23/9568 (0.2%) patients at 30 
days, with an adjusted odds ratio of 0.48 (95% CI, 0.29–
0.80; P=0.005). The upper limit of our 1-sided 95% CI 
for the adjusted risk difference was –0.13%, which was 
below our superiority margin of 0%. The secondary safety 
outcome occurred in 251/8673 (2.9%) and 161/9568 
(1.7%) patients at 1 year (adjusted odds ratio, 0.58 [95% 
CI, 0.47–0.71]; P<0.001).
DISCUSSION
We evaluated the efficacy and safety of implementing 
an early rule-out pathway in 31 492 consecutive pa-
tients presenting with suspected ACS to the emergency 
department or acute medical receiving unit. Introducing 
the pathway into clinical practice reduced length of stay 
by 3.3 hours and increased the odds of patients avoid-
ing hospital admission by 59%. Noninferiority was not 
formally demonstrated, but the observed differences in 
MI or cardiac death after discharge favored the early 
rule-out pathway.
Our pragmatic trial design has several strengths. First, 
we embedded our screening tool into the patient record 
to ensure that we prospectively enrolled consecutive 
patients in whom the attending clinician suspected ACS. 
This minimized the risk of selection bias, ensuring that we 
did not limit our findings to low-risk patients or those pre-
senting within working hours. Second, because the inter-
vention was implemented at the hospital level, we did not 
seek individual patient consent. This reduced the risk of 
a Hawthorne effect, where effectiveness is exaggerated 
through direct observation of clinical care by researchers. 
Third, our trial population was larger than the combined 
number of patients enrolled in 30 previous observational 
studies.27,28 This ensured we had a greater number of 
events to evaluate safety. Last, we combined hospital-
level data with established registries to ensure follow-up 
was complete in 99.8% of participants and that our panel 
was able to adjudicate all safety outcome events.
Figure 2. The HiSTORIC trial Consolidated Standards of 
Reporting Trials diagram.
HiSTORIC indicates High-Sensitivity Cardiac Troponin on 
Presentation to Rule Out Myocardial Infarction; and hs-cTnI, high-
sensitivity cardiac troponin I.
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Table 1. Characteristics of the Trial Participants
Characteristics All Standard care Early rule-out
Participants, n 31 492 14 700 16 792
Age, y 59±17 59±17 58±17
Women 14 252 (45) 6575 (45) 7677 (46)
Presenting complaint
 Chest pain 26 590 (84) 12 566 (85) 14 024 (84)
 Dyspnea 957 (3) 420 (3) 537 (3)
 Palpitation 928 (3) 432 (3) 496 (3)
 Syncope 1701 (5) 699 (5) 1002 (6)
 Other 1316 (4) 583 (4) 733 (4)
Medical history
 Myocardial infarction 2573 (8) 1371 (9) 1202 (7)
 Ischemic heart disease 7346 (23) 3834 (26) 3512 (21)
 Cerebrovascular disease 1684 (5) 849 (6) 835 (5)
 Diabetes mellitus 1912 (6) 1002 (7) 910 (5)
Previous revascularization
 PCI 2831 (9) 1534 (10) 1297 (8)
 CABG 452 (1) 240 (2) 212 (1)
Medications at presentation
 Aspirin 8023 (25) 4114 (28) 3909 (23)
 Dual antiplatelet therapy* 1269 (4) 738 (5) 531 (3)
 Statin 12 165 (39) 6035 (41) 6130 (37)
 ACE inhibitor or ARB 9769 (31) 4776 (32) 4993 (30)
 β-blocker 8548 (27) 4162 (28) 4386 (26)
 Oral anticoagulant† 2167 (7) 1033 (7) 1134 (7)
ECG‡
 Normal 12 035 (74) 6118 (73) 5917 (75)
 Myocardial ischemia 3288 (20) 1756 (21) 1532 (20)
 ST-segment elevation 193 (1) 111 (1) 82 (1)
 ST-segment depression 252 (2) 146 (2) 106 (1)
 T-wave inversion 1225 (8) 621 (7) 604 (8)
 Other 1711 (11) 927 (11) 784 (10)
Hematology and clinical chemistry
 Hemoglobin, g/L 137±22 137±20 137±23
 eGFR, mL/min 81±22 81±23 82±22
 Presentation hs-cTnI, ng/L 3 (1, 6) 3 (1, 6) 3 (1, 6)
 Peak hs-cTnI, ng/L 3 (1, 7) 3 (1, 7) 3 (1, 7)
 Serial (≥2) tests§ 11 904 (38) 6540 (44) 5364 (32)
Time intervals
 Symptom onset to presentation ≤2 hours 5664 (18) 2859 (19) 2805 (17)
 Presentation to first test, min 66 (45, 97) 66 (46, 97) 65 (43, 97)
 First to second test, min 351 (188, 553) 455 (267, 601) 229 (155, 405)
Values presented are n (%), mean±SD, or median (25th percentile, 75th percentile). ACE indicates angiotensin-con-
verting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; eGFR, estimated glomerular 
filtration rate; hs-cTnI, high-sensitivity cardiac troponin I; and PCI, percutaneous coronary intervention. 
*Two medications from aspirin, clopidogrel, prasugrel, or ticagrelor. 
†Includes warfarin or novel oral anticoagulants. 
‡Proportions reported for the 16 217 (51%) participants with ECG data available. 
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The High-STEACS early rule-out pathway, which deter-
mines whether a patient with suspected ACS requires 
hospital admission or can be safely discharged, is based 
on 3 principles. First, patients with very low troponin con-
centrations are at low risk of cardiac events.6 We defined 
the optimal risk stratification threshold as the highest 
concentration that gave a negative predictive value of 
>99.5% for MI or cardiac death at 30 days8,27 to maxi-
mize the effectiveness of this approach while maintaining 
safety. Second, increasing concentrations above this risk 
stratification threshold on repeat testing may be important, 
even if they remain within the normal reference range, and 
these patients require admission to measure peak tropo-
nin concentration.19 We define this using a change in con-
centration of ≥3 ng/L, based on the lowest measurable 
change that exceeds biological and analytic variation.29 
Third, to ensure our pathway is consistent with interna-
tional guidelines,4 we applied the sex-specific 99th per-
Table 2. Efficacy and Safety Outcomes at 30 Days and 1 Year
Outcomes All Standard care Early rule-out
Adjusted odds 
ratio (95% CI)* P value
Participants, n 31 492 14 700 16 792   
Efficacy outcome
 Length of stay, h (primary) 8.2±4.1 10.1±4.1 6.8±4.1 0.78 (0.73–0.83) <0.001
  Discharge from the  emergency 
department (secondary)
19 249 (61) 7407 (50) 11 842 (71) 1.59 (1.45–1.75) <0.001
Safety outcome†
 30 days (primary) 113 (0.4) 57 (0.4) 56 (0.3) 1.97 (0.95–4.08) 0.068
 1 year (secondary) 703 (2.2) 396 (2.7) 307 (1.8) 1.02 (0.74–1.40) 0.894
Other safety outcomes at 1 year
 Myocardial infarction‡ 422 (1.3) 238 (1.6) 184 (1.1) 1.10 (0.72–1.68) 0.646
 Cardiac death 319 (1.0) 176 (1.2) 143 (0.9) 1.07 (0.69–1.64) 0.771
 Cardiovascular death 452 (1.4) 249 (1.7) 203 (1.2) 0.93 (0.66–1.32) 0.696
 All-cause death 1720 (5.5) 852 (5.8) 868 (5.2) 0.92 (0.75–1.12) 0.385
 Unplanned revascularization§ 222 (0.7) 119 (0.8) 103 (0.6) 0.60 (0.35–1.03) 0.065
 Any hospital reattendance 12 306 (39.1) 5770 (39.3) 6536 (38.9) 0.93 (0.84–1.02) 0.112
Presented as geometric mean±SD or n (%). 
*Outcomes after implementation of the early rule-out pathway are compared with those during standard care for all measures. For 
length of stay, this is an adjusted ratio of the geometric mean rather than an odds ratio.
†Type 1, type 4b, or type 4c myocardial infarction or cardiac death after discharge.
‡Type 1, type 4b, or type 4c myocardial infarction.
§Unplanned revascularization was defined as urgent or emergency percutaneous coronary intervention or coronary artery bypass 
grafting from discharge to 1 year.
Figure 3. Length of stay before and 
after implementation of the early 
rule-out pathway.
Shown is a density plot of the length of 
stay in patients evaluated before (blue) 
and after (red) implementation of the 
early rule-out pathway. hs-cTnI indicates 
high-sensitivity cardiac troponin I; and 
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centile as the threshold to identify patients who require 
hospital admission. Adherence was good across all 7 
acute care hospitals, which is testament to the simplicity 
of the pathway and should encourage adoption.
Whereas many pathways that incorporate separate 
risk stratification and diagnostic thresholds have been 
described,12,30–32 these have the same limitation as the High-
STEACS pathway: no patient was managed according to 
these pathways during their derivation or validation. Guide-
line recommendations have therefore been based largely on 
observational data, with little understanding of the effect of 
these pathways in clinical practice. Here we evaluated the 
implementation of an early rule-out pathway in a prospec-
tive randomized controlled trial of consecutive patients. We 
report substantial reductions in length of stay and increases 
in the proportion of patients avoiding hospital admission. 
Were these gains to be realized across health care systems, 
the benefits for both patients and providers would be sub-
stantial. In the United States alone, >20 million patients with 
suspected ACS attend emergency departments every year.1 
A reduction in the length of stay of 3 hours could save >$3.6 
billion per annum on bed occupancy alone.33
Despite these important reductions in length of stay, 
during the implementation phase the median stay was 6.8 
hours, which is longer than reported in other evaluations of 
the implementation of early rule-out pathways.15,16,34 This 
difference likely reflects our enrollment of all consecutive 
patients rather than selected patients who are less likely 
to have comorbid conditions requiring hospital admission. 
We also acknowledge that reductions in length of stay 
may differ in other health care settings. Although the Euro-
pean Society of Cardiology guidelines have recommended 
high-sensitivity cardiac troponin testing and a 0/3-hour 
pathway based on the 99th percentile since 2011,35 we 
did not adopt this as our standard of care, but instead fol-
lowed the recommendations of our national guidelines.18 
During the design phase of the trial, we prospectively 
validated the European Society of Cardiology 0/3-hour 
high-sensitivity cardiac troponin pathway and demon-
strated that the diagnostic performance of serial testing at 
presentation and 3 hours compared with serial testing at 
presentation and 6 to 12 hours after symptom onset was 
poor, with a sensitivity and negative predictive value for 
MI of 89.3% and 97.9%, respectively.19 Our findings were 
consistent with those from an independent validation in 
Australia and New Zealand,36 and as a consequence the 
2020 European Society of Cardiology guidelines no lon-
ger indicate a preference for this approach.37 It is essential 
that more prospective trials are conducted in which clinical 
decisions are guided by new diagnostic approaches if we 
are to ensure our clinical practice guidelines are based on 
the highest-quality evidence.
Implementation of our early rule-out pathway did not 
increase the rate of subsequent MI or cardiac death. How-
ever, our results were highly sensitive to the model speci-
fication. Although noninferiority was not concluded for the 
primary safety outcome at 30 days, in our prespecified 
sensitivity analysis restricted to calendar-matched periods, 
Figure 4. Myocardial infarction or 
cardiac death after discharge before 
and after implementation of the early 
rule-out pathway.
Shown are cumulative incidence time-
to-event curves for the primary safety 
outcome of myocardial infarction or cardiac 
death for patients evaluated before (blue 
line) and after (red line) implementation of 
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the early rule-out pathway was superior to standard care 
at 30 days and 1 year. These divergent results may be 
attributable to the low event rate at 30 days and narrow 
randomization phase leading to overfitting of the primary 
analysis model, additional secular changes not accounted 
for in the sensitivity analysis, or a true exposure–time effect 
whereby outcomes improved as the intervention became 
more firmly embedded into practice. We acknowledge that 
although the number of patients enrolled in each cluster 
(hospital) was large, the number of clusters was small, 
which may have made the trial more vulnerable to the 
effect of confounding bias occurring within individual sites. 
However, our analyses suggested that including site as a 
random effect in the model had negligible influence on the 
overall result. The low event rate for the safety outcome at 
30 days and narrow randomization phase made it more 
likely for chance imbalances to occur between those man-
aged according to the standard care and early rule-out 
pathway (Figure II in the Data Supplement). This may have 
produced partial confounding of our estimate of the effect 
of the intervention because the primary analysis model 
incorporates both vertical comparisons across sites as 
well as before-and-after comparisons within sites. We also 
prespecified a calendar-matched before-and-after sensi-
tivity analysis that did not include a vertical comparison, 
the results of which favored the early rule-out pathway.
Is it plausible that the introduction of an early rule-out 
pathway could reduce the risk of subsequent cardiac 
events? By using a threshold well below the 99th percen-
tile to risk stratify patients and by recognizing that small 
changes in troponin concentration within the reference 
range may be important, we may have improved the eval-
uation of risk compared with using a single higher thresh-
old to rule in and rule out MI. This is supported by recent 
observational studies, which report that using the 99th 
percentile to rule out MI at presentation and at 3 hours 
misses 1 in 10 patients with MI who would have been 
identified on serial testing 6 to 12 hours after the onset 
of symptoms.19,36,38 Furthermore, our pathway encourages 
serial testing to rule out MI in early presenters, which is 
now recognized by international guidelines.37,39
Our findings add to those from 2 recently published 
randomized trials. The RAPID-TnT trial (Rapid Assessment 
of Possible ACS in the Emergency Department With High-
Sensitivity Troponin T) compared a 1-hour and 3-hour 
rule-out pathway in 3378 patients, finding a 1-hour strat-
egy reduced length of stay by 60 minutes and increased 
discharge rates from 32% to 45%.16 The trial concluded 
noninferiority for an end point of all-cause mortality or MI 
within 30 days, although there was an increase in sec-
ondary safety outcome events in the 1-hour pathway arm. 
Because of a perceived lack of equipoise, the monitoring 
committee recommended the trial stop recruitment with 
just two-thirds of the target population enrolled, and only 
1 patient had a type 1 MI after discharge in each arm. 
The LoDED trial (Limit of Detection and ECG Discharge) 
compared standard guideline care with a rule-out path-
way using the limit of detection of cardiac troponin in 
632 patients.40 The use of a single test approach did not 
increase the proportion of patients discharged from hos-
pital within 4 hours of presentation. This surprising finding 
may have been attributable to the small sample size and 
insufficient power or the enrollment of selected lower risk 
patients with a normal ECG. It appears that the treating 
clinician determined the probability of MI to be sufficiently 
low that admission to hospital was not required in both 
arms of the trial. However, consistent with our observa-
tions, the LoDED investigators report that a single test 
approach was acceptable to patients and clinicians and 
that pathway adherence was excellent.
We acknowledge several potential study limitations. First, 
whereas the early rule-out pathway was implemented across 
3 steps in the randomization phase, we had to accept flex-
ibility in the date of implementation (Expanded Methods in 
the Data Supplement). This limited our ability to interpret a 
planned sensitivity analysis within the randomization phase, 
when there were sites using both the standard care and 
early rule-out pathway. Second, we enrolled fewer than the 
38 994 patients anticipated in our sample size calculations, 
and identified fewer safety outcome events at 30 days. This 
in part contributed to modeling issues when attempting to 
evaluate the safety outcome at 30 days. However, >700 
patients had a MI or cardiac death at 1 year, and the rates 
of all secondary outcome measures were lower after imple-
mentation of the early rule-out pathway. Third, the standard 
care arm of our trial used a serial testing strategy based 
on the time of onset of symptoms, rather than a fixed time 
point 3 to 6 hours from presentation, which is more com-
monly used in other countries. Despite this limitation, 50% 
of patients were discharged directly from the emergency 
department in our standard care arm. Whereas there are 
differences in the inclusion criteria between trials, the pro-
portion of patients discharged in our standard care arm was 
already higher than in either arm of the RAPID-TnT trial, 
which compared a 0/3-hour pathway (32% discharged) 
with a 0/1-hour pathway (45% discharged).16 Despite the 
high proportion of patients discharged in our standard care 
arm, we increased the proportion discharged from 50% to 
71% when implementing our early rule-out pathway. Fourth, 
our early rule-out pathway does not recommend early serial 
testing in those with elevated cardiac troponin concentra-
tions at presentation. In our previous trial,17 we observed 
that 2.7% of patients with suspected ACS have evidence of 
chronic myocardial injury.41 It is possible the effectiveness of 
our pathway could be further improved if these patients were 
identified in the emergency department. However, patients 
with chronic myocardial injury are complex with significant 
cardiac and noncardiac comorbidities and may benefit from 
further evaluation before discharge. Additional research 
is needed to evaluate the effectiveness of approaches to 
improve the ruling in of MI.12,42 Last, our pathway has been 
validated for use with 2 troponin I assays and a troponin T 
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assay without modification,19,20,43,44 and although it is likely 
to perform similarly for other high-sensitivity assays, further 
research is required to confirm this.
Implementation of an early rule-out pathway for MI 
substantially reduced length of stay and increased the 
proportion of patients avoiding hospital admission with 
no increase in adverse cardiac events. Adoption of this 
approach would have important benefits for both patients 
and health care providers.
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